- Anglicus
- Gallus
- Germanus
- Portuguese
- Spanish
- Russian
- Iaponica
- Coreanica
- Arabic
- Hibernica
- Graeculus
- Turkish
- Italiae
- DANICULUS
- Romanian
- Indonesiaca
- Bohemica
- Africikaans
- SCELIDUS
- POLICULO
- Basque
- Catalana
- Esperanto
- Hindi
- Lago
- Illyrica
- Amharicus
- Armeniana
- Azerbaieni
- Belarusian
- Bengalica
- BOSNIAN
- Bulgarica
- Cebuano
- Chichewa
- Corsican
- Crovatica
- Batavica
- Estonian
- Philippinica
- Fennica
- Frisian
- Gallaeca
- Georgian
- Gujarati
- Haitiaian
- Hausa
- HAWAIUS
- Hebraica
- Hmong
- Hungarian
- IMETIANICUS
- Igbo
- Javanese
- Cannada
- Kazakh
- Khmer
- Kurdica
- Kyrgyz
- Latine
- Latvian
- Lithuanian
- Lithuanian
- Macedonian
- MALAGASUS
- Malae
- Malayalam
- Melitensis
- Maorice
- Marathi
- Mongolica
- Burmese
- Nepalica
- Norwegian
- Pastua
- Persicus
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Moravica
- Carnica
- Somali
- Samoan
- Scoti Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ucraina
- Urdu
- Uzbek
- Vietnamica
- Cambrica
- Xhosa
- LOKINDIS
- Yoruba
- Zuluensis
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
SAGACITAS TRC - T
Development Historia de TCR - T cellula Therapy
In MMII, Rosenberg scriptor quadrigis erat primus ut reveles Tumor - infiltrating lymphocytes (tils) separatim a melanoma potest specie interficere tumor cellulis cum amplificari et transfunda in vitro. Tamen, in alias natalis, sicut et saepe difficile ad obtinendum et longum tempus expand in vitro. Most eorum sunt terminatio diversificatur T cellulis post expansion, et sustinuit anti - tumor effectus est infirma. In hoc contextu, qui sunt explorantes utrum notum Antigen - specifica TCR gene potest introduci in normalis periphericis sanguis lymphocytes (PBL) pro curatio, quod est TCR - T cellula therapy.
In progressionem processus of TCR - T technology, quattuor iterations sunt periti:
Prima generatio TCR - T est separatim ab T cellulis de aegris cum tumore antigen specifica recognition of T cellula, expanded in vitro et deinde transfunditur retro ad curatio. Propter parva numerus T cellula clones et magnis differentias, difficile est industriae.
Secundum generationem TRD - T est clone in T cellulis specie agnita est supra tumore antigen, adipisci tCR gene sequence et deinde transferendum est periphericis T cellulis aegris. Hoc modum facit industriarum TRC - T potest.
Tertium TRD - T est ad amplio druggability TCR - T per optimizing affinitate TCT, faciens melius possit agnoscis tumore antigens et traducendo ad patientes estote T cellulis.
Quartum - Generation TCR - T est a summo specifica cell therapy targeting tumore neoantigens, cum significantly melius tumore responsio et salus.
Quid TCT - T cellula Therapy
TCR-T cell therapy, short for T cell receptor-engineered T cells, is based on gene editing technology to specifically recognize tumor antigen T cell receptors（TCR ）gene, be introduced into the patient's own T cells to make them express exogenous TCR, so as to recognize and attack tumor cells and achieve the purpose of tumor treatment.
